🔗 Share this article

As the United States proceeds with historic revisions to its vaccine schedules, an unexpected name appears unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by casting doubt on coronavirus shots throughout the pandemic and has zeroed in on possible deaths after COVID-19 vaccination in her recent time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Immunization Schedule

Health officials were set to announce major changes to the pediatric vaccine schedule recently, bringing the US with Denmark’s vaccine program, according to reports – a significant shift that would place the US out of alignment with many the world with no evidence for public health gain. The announcement has been pushed back until the new year.

Rather than the director of the vaccine center, Høeg is scheduled to address the audience at the gathering. She was just designated acting director of the FDA’s drug evaluation center, the fifth person to head the office this calendar year.

A Shift at the Regulatory Body

This interim role may indicate a closer partnership between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad consolidate power at the agency – and it points to a greater focus upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for discontinuing specific childhood vaccine recommendations in the US so as to align more similar to Denmark's approach, a nation with universal health coverage and a number of inhabitants about the size of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on vaccines – typically the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Concerns Over Qualifications

Dr. Høeg has little discernible experience in pharmaceutical research, regulation or administrative roles, which has been customary for former leaders of the CBER. She has served at the FDA as a key advisor to the agency head and the vaccine center since March.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in running a sizeable institution. She is not an expert in drug approvals.”

Former directors of the center would “be deeply familiar with regulatory frameworks and the research of drug development”, commented Janet Woodcock. “Frankly, she has not acquired the sort of resume that previous people who headed the center have had.”

This division has an enormous portfolio at the FDA, the former commissioner pointed out.

“Everybody just zeroes in on the new drug program, but the generic drug division approves numerous generic medications. There’s a biologic copycat branch, non-prescription drug unit and so forth, and every single one need to be supervised,” she said. “The area you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant management component to the position, which oversees more than 5,000 personnel. “It is a huge management job, if you perform it correctly,” she added.

Agency Reaction and Disputed Programs

Regarding questions about Høeg’s fitness for the role and whether this appointment signifies increased cooperation among FDA leaders on vaccines, a spokesperson said that the “concerns stem from inaccurate assumptions”.

“Her resume is consistent with the functions of her job,” the spokesperson said, citing the months Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the commissioner’s new expedited review system, a disputed one-day therapy clearance system that allegedly worried her predecessors. “How are these medications being picked for this voucher program? Who is making the calls?” Dr. Howard asked. “There’s a lot of secrecy going on at the FDA right now.”

Broadly speaking, he remarked, “the Food and Drug Administration appears to be shifting towards more relaxed rules of most medications, with the exception of immunizations.”

Established History on Immunizations

With immunizations, Dr. Høeg has a clearer, if troubling, past, Howard said. She published a analysis using unverified public submissions to estimate the frequency of heart inflammation following COVID-19 immunization. She consulted for the Florida chief medical officer Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccines are more dangerous than they are.

Included in her “desired changes” for the incoming federal leadership encompassed changing regulations for recently developed shots and ending “optional” vaccines, she remarked post-election on a online show. At the agency, Høeg has reportedly proposed barring teenage boys from getting COVID-19 vaccines.

“She’s an complete dogmatist who begins with her beliefs and reverse-engineers to accommodate the data in a highly misleading, untruthful way,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg became part of fellow contrarians, {like|